9 Things Women With Migraine With Aura Must Know Before Starting HRT
Getting the 'you have migraine with aura, so HRT is complicated' news in the middle of already feeling terrible is a lot to process. What helped most was understanding that this isn't a hard no — it's a 'let's be specific about how.' That distinction matters enormously when you're exhausted and just want to feel like yourself again.
Learn more about Rose →Migraine With Aura Is Classified as an Independent Stroke Risk Factor — Full Stop
Unlike migraine without aura, migraine with aura is associated with a roughly doubled risk of ischemic stroke in women, independent of other cardiovascular risk factors. This relationship is well-established in large epidemiological studies and is why neurologists and cardiologists treat it as a vascular condition, not just a pain condition. Understanding this baseline risk is the foundation of every HRT decision that follows.
Oral Estrogen Has a Different Risk Profile Than Transdermal Estrogen — and That Difference Matters Here
Oral estrogen passes through the liver on first pass, which increases clotting factor production and raises the risk of venous thromboembolism and, importantly for aura sufferers, ischemic stroke. Transdermal estrogen — patches, gels, sprays — bypasses the liver entirely, resulting in a much more stable estrogen level in the bloodstream without the same prothrombotic effect. For women with migraine with aura, this route distinction is not a minor detail; it is the central safety question.
Current Evidence Suggests Transdermal Estrogen Does Not Significantly Increase Stroke Risk in This Group
Several large observational studies, including the landmark ISCHAEMIC study and data from the UK's Clinical Practice Research Datalink, found no meaningful increase in ischemic stroke risk with transdermal estrogen use compared to non-use, even in women with migraine with aura. This does not mean zero risk, but it represents a substantially safer profile than oral preparations for this specific population. Many neurologists and menopause specialists now consider transdermal estrogen the preferred route — not the forbidden one — for women in this group.
The Type of Progestogen in Combined HRT Also Deserves Scrutiny
Women who still have a uterus need a progestogen alongside estrogen to protect the uterine lining, but not all progestogens behave the same way in the vascular system. Synthetic progestins — particularly older ones like medroxyprogesterone acetate — have been associated with less favorable cardiovascular profiles, while micronised progesterone (body-identical progesterone) appears to have a more neutral or even beneficial effect on blood vessels and coagulation. For women with migraine with aura, micronised progesterone is generally the preferred progestogen choice, though prescribing decisions should always be individualised.
Perimenopausal Hormone Fluctuations Can Actually Make Migraine With Aura Worse Before HRT Helps
Estrogen withdrawal — the sharp, erratic drops that characterise perimenopause — is a well-documented migraine trigger, and women with aura are particularly sensitive to these fluctuations. This is why many women find their migraines intensify in perimenopause even before they start thinking about HRT. Stabilising estrogen levels through a steady transdermal dose can reduce the frequency and severity of attacks for some women, which is one of the reasons HRT is not automatically off the table — used correctly, it may actually help.
Stroke Risk Is Multiplicative, Not Additive — Know Your Full Risk Picture
Migraine with aura sits alongside other stroke risk factors — smoking, hypertension, obesity, atrial fibrillation, diabetes — and these risks multiply rather than simply add up. A woman with migraine with aura who also smokes and has uncontrolled hypertension is in a meaningfully different risk category than a woman whose only risk factor is the aura itself. Before starting any HRT, a thorough cardiovascular risk assessment — including blood pressure measurement and a frank conversation about lifestyle factors — is essential context for the prescribing decision.
A Neurologist and a Menopause Specialist Should Ideally Both Be Involved in the Prescribing Decision
In practice, HRT is often prescribed by a GP or gynaecologist who may not have deep familiarity with the neurovascular specifics of migraine with aura, while neurologists managing migraines may not be up to date on the latest menopause hormone evidence. Getting both perspectives — or at minimum ensuring the prescribing clinician has actively reviewed the neurology — produces safer, more personalised decisions. Women should feel empowered to ask their prescriber whether they have considered the aura classification specifically, and to request a referral if the answer is uncertain.
A New or Changed Aura Pattern After Starting HRT Is a Red Flag That Needs Same-Day Assessment
While starting or adjusting HRT can sometimes temporarily change migraine patterns as hormone levels stabilise, any new neurological symptom — a first-ever aura, an aura that is longer than 60 minutes, weakness or speech changes accompanying the aura, or a sudden severe headache unlike previous migraines — should be treated as a potential neurological emergency. The FAST acronym (Face drooping, Arm weakness, Speech difficulty, Time to call 999/911) applies here regardless of whether a migraine has always been part of the picture. Women and their families should know this threshold before HRT begins.
Not Having HRT Is Also a Risk — the Calculus Is Never One-Sided
Untreated menopause symptoms carry their own health consequences: poor sleep compounds cardiovascular risk, vasomotor symptoms are linked to increased blood pressure spikes, and bone density loss begins accelerating without estrogen. For women who dismiss HRT entirely because of migraine with aura, the risk of doing nothing deserves the same rigorous examination as the risk of the wrong type of HRT. The goal of the conversation with a clinician is not to find a reason to refuse treatment but to identify the safest path to managing the transition — which, for many women with aura, genuinely exists.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.